The False Claims Act reaches past the corporate entity and into the individual executive's own finances. The statute, codified at 31 U.S.C. § 3729, imposes liability on "any person" who knowingly presents or causes to be presented a false claim, and courts have applied that language to CEOs, CFOs, compliance officers, and other executives who had a hand in the conduct at issue. Treble damages and per-claim civil penalties apply to individuals exactly as they apply to the company, and neither a corporate title nor a delegation of the task to subordinates automatically forecloses personal exposure.
The Statutory Basis for Individual Liability
The False Claims Act defines "knowingly" to include actual knowledge, deliberate ignorance of the truth, and reckless disregard of the truth, and the statute requires no proof of specific intent to defraud. The Supreme Court sharpened that standard in United States ex rel. Schutte v. SuperValu Inc. (2023), holding that the FCA's scienter element turns on the defendant's own subjective knowledge and beliefs, not on whether an objectively reasonable person might have read the applicable rule differently. For an executive, that means a genuinely held but wrong interpretation of a billing rule is a weaker shield than it once looked, if the record shows the executive privately doubted that interpretation while it was in use.
DOJ's Individual Accountability Policy
Department of Justice policy has directed civil and criminal attorneys to pursue individuals since the September 2015 "Individual Accountability for Corporate Wrongdoing" memorandum (the Yates Memo), which made cooperation credit for a company contingent on disclosing all relevant facts about the individuals involved, and directed that civil and criminal investigations identify responsible individuals from the outset. The Department's 2022 revisions to corporate criminal enforcement policy kept that framework in place. In an FCA matter, that policy shows up as a civil complaint or settlement naming the executive personally, alongside or apart from the entity. DOJ recovered $6.8 billion in False Claims Act settlements and judgments in fiscal year 2025, with $5.7 billion of that tied to healthcare matters, the largest annual total in the statute's history, and individual defendants are increasingly part of how those cases resolve. A qui tam relator's complaint can name an executive by name from the outset, well before the government decides whether to intervene.
An executive's personal exposure under the False Claims Act turns on what that executive actually knew, or deliberately avoided knowing, about the claims being submitted, not on the title on the door.
Indemnification Limits and Insurance Coverage Questions
Corporate bylaws and indemnification agreements routinely promise to cover an officer's legal costs and liabilities incurred in the course of employment, but that promise runs into a hard limit when the underlying conduct is the same knowing or reckless conduct the FCA penalizes. Courts have repeatedly held that indemnification or contribution for the defendant's own FCA liability is unavailable as a matter of public policy, on the reasoning that letting a wrongdoer shift the penalty back onto the company would gut the statute's deterrent purpose. Directors and officers (D&O) insurance occupies a narrower lane than most executives assume. Fraud and criminal-conduct exclusions in standard D&O policies typically bar coverage once a final adjudication establishes the underlying dishonesty, and insurers frequently dispute coverage for FCA exposure long before that point is reached. Whether a given policy responds at all often depends on how the claim is framed in the complaint and how early defense counsel engages with the carrier, which is a question distinct from civil versus criminal FCA exposure, where the available insurance and indemnification options diverge even further.
Why Early Legal Counsel Is Critical
It is critical that healthcare executives promptly retain experienced healthcare defense counsel upon receiving a subpoena, civil investigative demand, audit notice, or other government inquiry that touches their personal conduct. Early legal intervention can protect the executive's individual rights, ensure appropriate and accurate responses to government requests, avoid inadvertent admissions that later support a scienter finding, preserve every available defense, and let counsel communicate with investigators on the executive's behalf rather than the company's. Delaying representation can significantly affect the outcome of a matter and expose the executive to unnecessary personal risk, including program OIG exclusion that follows the individual even after any corporate settlement is final.
How Health Law Alliance Can Help
Health Law Alliance defends healthcare executives and the companies they lead against False Claims Act investigations, qui tam suits, and government-initiated actions, including matters where an individual officer faces personal exposure separate from the entity's. Our attorneys evaluate indemnification agreements, coordinate with D&O carriers where coverage is available, and represent executives from the first subpoena through resolution. If you are an executive or compliance officer facing personal exposure under the False Claims Act, contact us for a free, confidential consultation.
